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Abstract: Prions are transmissible agents causing lethal neurodegenerative diseases that are composed
of aggregates of misfolded cellular prion protein (PrPSc). Despite non-fibrillar oligomers having been
proposed as the most infectious prion particles, prions purified from diseased brains usually consist of
large and fibrillar PrPSc aggregates, whose protease-resistant core (PrPres) encompasses the whole C-
terminus of PrP. In contrast, PrPSc from Gerstmann-Sträussler-Scheinker disease associated with alanine
to valine substitution at position 117 (GSS-A117V) is characterized by a small protease-resistant core,
which is devoid of the C-terminus. We thus aimed to investigate the role of this unusual PrPSc in terms of
infectivity, strain characteristics, and structural features. We found, by titration in bank voles, that the
infectivity of GSS-A117V is extremely high (109.3 ID50 U/g) and is resistant to treatment with proteinase
K (109.0 ID50 U/g). We then purified the proteinase K-resistant GSS-A117V prions and determined the
amount of infectivity and PrPres in the different fractions, alongside the morphological characteristics of
purified PrPres aggregates by electron microscopy. Purified pellet fractions from GSS-A117V contained
the expected N- and C-terminally cleaved 7 kDa PrPres, although the yield of PrPres was low. We found
that this low yield depended on the low density/small size of GSS-A117V PrPres, as it was mainly retained
in the last supernatant fraction. All fractions were highly infectious, thus confirming the infectious nature
of the 7 kDa PrPres, with infectivity levels that directly correlated with the PrPres amount detected.
Finally, electron microscopy analysis of these fractions showed no presence of amyloid fibrils, but only
very small and indistinct, non-fibrillar PrPresparticles were detected and confirmed to contain PrP via
immunogold labelling. Our study demonstrates that purified aggregates of 7 kDa PrPres, spanning
residues ฀90–150, are highly infectious oligomers that encode the biochemical and biological strain features
of the original sample. Overall, the autocatalytic behaviour of the prion oligomers reveals their role in the
propagation of neurodegeneration in patients with Gerstmann-Sträussler-Scheinker disease and implies
that the C-terminus of PrPSc is dispensable for infectivity and strain features for this prion strain,
uncovering the central PrP domain as the minimal molecular component able to encode infectious prions.
These findings are consistent with the hypothesis that non-fibrillar prion particles are highly efficient
propagators of disease and provide new molecular and morphological constraints on the structure of
infectious prions.
DOI: https://doi.org/10.1093/brain/awaa078






The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Vanni, Ilaria; Pirisinu, Laura; Acevedo-Morantes, Claudia; Kamali-Jamil, Razieh; Rathod, Vineet; Di
Bari, Michele Angelo; D’Agostino, Claudia; Marcon, Stefano; Esposito, Elena; Riccardi, Geraldina;
Hornemann, Simone; Senatore, Assunta; Aguzzi, Adriano; Agrimi, Umberto; Wille, Holger; Nonno,
Romolo (2020). Isolation of infectious, non-fibrillar and oligomeric prions from a genetic prion disease.
Brain: a journal of neurology, 143(5):1512-1524.
DOI: https://doi.org/10.1093/brain/awaa078
2
Isolation of infectious, non-fibrillar and
oligomeric prions from a genetic prion disease
Ilaria Vanni,1 Laura Pirisinu,1 Claudia Acevedo-Morantes,2 Razieh Kamali-Jamil,2
Vineet Rathod,2 Michele Angelo Di Bari,1 Claudia D’Agostino,1 Stefano Marcon,1
Elena Esposito,1 Geraldina Riccardi,1 Simone Hornemann,3 Assunta Senatore,3
Adriano Aguzzi,3 Umberto Agrimi,1 Holger Wille2 and Romolo Nonno1
Prions are transmissible agents causing lethal neurodegenerative diseases that are composed of aggregates of misfolded cellular
prion protein (PrPSc). Despite non-fibrillar oligomers having been proposed as the most infectious prion particles, prions purified
from diseased brains usually consist of large and fibrillar PrPSc aggregates, whose protease-resistant core (PrPres) encompasses the
whole C-terminus of PrP. In contrast, PrPSc from Gerstmann-Sträussler-Scheinker disease associated with alanine to valine substitu-
tion at position 117 (GSS-A117V) is characterized by a small protease-resistant core, which is devoid of the C-terminus. We thus
aimed to investigate the role of this unusual PrPSc in terms of infectivity, strain characteristics, and structural features. We found,
by titration in bank voles, that the infectivity of GSS-A117V is extremely high (109.3 ID50 U/g) and is resistant to treatment with
proteinase K (109.0 ID50 U/g). We then purified the proteinase K-resistant GSS-A117V prions and determined the amount of infect-
ivity and PrPres in the different fractions, alongside the morphological characteristics of purified PrPres aggregates by electron mi-
croscopy. Purified pellet fractions from GSS-A117V contained the expected N- and C-terminally cleaved 7 kDa PrPres, although the
yield of PrPres was low. We found that this low yield depended on the low density/small size of GSS-A117V PrPres, as it was mainly
retained in the last supernatant fraction. All fractions were highly infectious, thus confirming the infectious nature of the 7 kDa
PrPres, with infectivity levels that directly correlated with the PrPres amount detected. Finally, electron microscopy analysis of these
fractions showed no presence of amyloid fibrils, but only very small and indistinct, non-fibrillar PrPresparticles were detected and
confirmed to contain PrP via immunogold labelling. Our study demonstrates that purified aggregates of 7 kDa PrPres, spanning res-
idues 90–150, are highly infectious oligomers that encode the biochemical and biological strain features of the original sample.
Overall, the autocatalytic behaviour of the prion oligomers reveals their role in the propagation of neurodegeneration in patients
with Gerstmann-Sträussler-Scheinker disease and implies that the C-terminus of PrPSc is dispensable for infectivity and strain fea-
tures for this prion strain, uncovering the central PrP domain as the minimal molecular component able to encode infectious
prions. These findings are consistent with the hypothesis that non-fibrillar prion particles are highly efficient propagators of disease
and provide new molecular and morphological constraints on the structure of infectious prions.
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Abbreviations: CJD = Creutzfeldt-Jakob disease; GPI = glycophosphatidylinositol; GSS = Gerstmann-Sträussler-Scheinker dis-
ease; PE = Pronase E; PK = proteinase K; PrPC = cellular prion protein; PrPSc = misfolded pathological isoform of the host-encoded
PrPC; TSESc = transmissible spongiform encephalopathy
Introduction
Transmissible spongiform encephalopathies (TSEs), or prion
diseases, are fatal neurodegenerative diseases, affecting
humans and animals, that are associated with CNS accumu-
lation of autocatalytically self-replicating aggregates of PrPSc,
a misfolded pathological isoform of the host-encoded cellu-
lar prion protein (PrPC) (Prusiner, 1998). Although TSEs
can occur as acquired, sporadic as well as inherited forms,
they have been historically defined based on their experi-
mental transmissibility. According to the protein-only hy-
pothesis, PrPSc is considered the main, if not the sole,
component of prions, the proteinaceous infectious agent of
TSEs. Sporadic forms of human prion diseases include
Creutzfeldt-Jakob disease (CJD) and the variably protease-
sensitive prionopathy (VPSPr), while the acquired forms in-
clude variant CJD and Kuru. Genetic CJD, fatal familiar in-
somnia (FFI) and Gerstmann-Sträussler-Scheinker disease
(GSS), are instead caused by pathogenic mutations in the
prion protein PRNP gene which predisposes mutant PrPC to
spontaneously convert to PrPSc.
For most human TSEs, the digestion of PrPSc with protein-
ase K (PK) results in PK-resistant PrP aggregates (PrPres) that
are composed of N-terminally truncated, variably glycosy-
lated C-terminal PrP fragments, with a molecular weight of
19–21 kDa for the non-glycosylated form (Parchi et al.,
1996). By contrast, a PrPSc variant with biochemical features
unique and distinctive from any other human prion disease
characterizes GSS and VPSPr. Indeed, these diseases are
characterized by an atypical PrPSc whose PK-resistant core is
composed of a non-glycosylated, C- and N-terminally trun-
cated PrP fragment, with a molecular weight that varies be-
tween 6 and 8 kDa depending on the specific PRNP
mutation (Piccardo et al., 1998, 2001; Gambetti et al.,
2011; Pirisinu et al., 2016). Among others, the GSS subtype
associated with an alanine to valine mutation at the
PRNP position 117 (GSS-A117V) is exclusively character-
ized by 6–7 kDa PrPres, composed of non-glycosylated PrP
fragments spanning amino acids 90–150 (Tagliavini et al.,
2001; Pirisinu et al., 2013; Cracco et al., 2019). As GSS
cases exclusively associated with 6–8 kDa PrPres have been
historically difficult to transmit in animal models, their na-
ture as TSEs and the autocatalytic behaviour of their atyp-
ical PrPSc has been debated. However, recent evidence of
their transmissibility to humanized mice (Asante et al.,
2013) and bank voles (Pirisinu et al., 2016) indicated that
these GSS subtypes are indeed true prion diseases.
A direct association between infectivity and PrPres had
been reported for most TSEs characterized by classical PrPSc
(Cronier et al., 2008; Lacroux et al., 2012; Miyazawa et al.,
2015), and a recent study conducted on recombinant PrPSc
confirmed and strengthened this association, demonstrating
that the infectivity is encoded only within the structure of
the PK-resistant, C-terminal, PrP fragment (Wang et al.,
2018). Despite the latest findings on the transmissibility of
prion diseases exclusively associated with 6–8 kDa PrPres, a
comparable association between infectivity and atypical
PrPres that lacks not only the N-terminus of the protein but
also its C-terminus is still lacking. Here, we took advantage
of the high susceptibility of bank voles to GSS and of a
newly published purification method (Wenborn et al., 2015)
to analyse the distribution of PrPres and infectivity during
the purification of 7 kDa PrPres aggregates from brains of
humans affected with GSS-A117V.
Our findings show that purified 7 kDa PrPres consists of
small, non-fibrillar, autocatalytic aggregates composed of
non-glycosylated and non-glycophosphatidylinositol (GPI)
anchored PrP fragments spanning amino acids 90–150, which
are solely responsible for the observed infectivity and encode
the strain properties of GSS prions. In addition to demonstrat-
ing that aggregates composed of N- and C-terminally trun-
cated PrP are truly infectious prions, our findings provide
new important constraints regarding the molecular architec-
ture that underlies the structure of infectious prions.
Material and methods
Prion isolates
Frozen brain samples from two GSS-A117V cases (samples
GSS-A117V #1 and GSS-A117V #2) and from a sporadic
CJD-MM1 case were provided by the National Prion
Disease Pathology Surveillance Centre (Cleveland, USA) and
the National Italian CJD Registry (Rome, Italy), respectively.
The use of material was approved by UHCMC IRB #05-14-
09, for the GSS cases, and by the Ethical Committee of the
Istituto Superiore di Sanità for the sporadic CJD case. The
PrP polymorphisms at position 129 were 129-VV and 129-
MV for GSS-A117V #1 and GSS-A117V #2, respectively,
and 129-MM for the sporadic CJD case. Bv109I-adapted
CWD (Bv-CWD) and Bv109I-adapted Scrapie (Bv-Scr) sam-
ples used for the purification were from terminally affected
Bv109I derived from previous studies (Di Bari et al., 2013).
Frozen brain samples from Bv109I healthy voles (Bv-Neg)
were also used for the purification as negative controls.
Preparation of brain homogenates
for titration assays
Brain tissues were homogenized at 10% w/v in a phosphate-
buffered saline (PBS) pH 7.4 and stored at –80C. For


























































































each sample, two aliquots were taken. Aliquots were supple-
mented with 2% sarkosyl and incubated with gentle shaking
at 37C for 10 min. For each sample, an aliquot was added
with 20 lg/ml PK (Sigma-Aldrich), while the untreated ali-
quot was added with an equal volume of PBS. Samples were
then incubated for 1 h at 37C with gentle shaking and the
treatment was stopped with 10 mM PMSF (Sigma Aldrich).
PK-treated and untreated brain homogenates from GSS-
A117V, sCJD-MM1 and Bv-CWD were diluted to 0.4% w/
v and then 10-fold serially diluted up to the dilution 4  10–
8.
Prion purification
Purified prion preparations were prepared as described in
Wenborn et al. (2015). Briefly, 200 ml aliquots of 10% w/v
brain homogenates were treated for 30 min with Pronase E
(PE) (Sigma-Aldrich) (100 lg/ml final concentration) with
gentle shaking at 37C. Digested samples were then added
to 10 mM EDTA and incubated with an equal volume of
sarkosyl 4% and BenzonaseV
R
(Merck) (50 U/ml final con-
centration) for 10 min at 37C. Iodixanol 60% and NaPTA
4% were added to give final concentrations in the sample of
35% (w/v) and 0.3% (w/v), respectively, and then centri-
fuged at 16100g for 90 min at 37C. After carefully remov-
ing the upper flocculate fraction, the solubilized supernatant
was filtered through a 0.45 lm membrane, mixed with an
equal volume of 2% (w/v) sarkosyl in Dulbecco’s PBS con-
taining 0.3% (w/v) NaPTA and then centrifuged at 16100g
for 90 min at 37C to obtain the semi-purified P2 pellet and
the SN2 supernatant fractions, which were used for western
blot and bioassay analysis.
We also used a modified version of this protocol in which
200 ml aliquots of 10% brain homogenate were first incu-
bated for 30 min with an equal volume of sarkosyl 4% with
gentle shaking at 37C and then treated with 50 lg/ml PK
for 60 min at 55C and gentle shaking. PK activity was
blocked by adding 3 mM PMSF for 10 min at 4C. The PK-
treated samples were then subjected to the same steps of the
Wenborn protocol that followed PE digestion, starting from
the BenzonaseV
R
treatment as described above, obtaining
again a semi-purified P2 pellet and the SN2 supernatant
fractions that were then used for the western blot, electron
microscopy and bioassay experiments. P2 pellets were resus-
pended in 20 ml PBS in the presence of 0.1% sarkosyl and
both the P2 and SN2 fractions were kept at –20C for west-
ern blotting and bioassay experiments. Considering the dis-
carded fractions of the protocol, a single 20 ml P2 aliquot,
as well as the corresponding SN2 fraction consisting of
1800 ml, corresponded to 150 ml of the starting brain hom-
ogenate (i.e. 15 mg brain equivalents).
With the PK protocol, P2 pellets were further purified to
obtain highly enriched pure PrPres preparations. To this aim,
P2 pellets were resuspended in a wash buffer composed of
Dulbecco’s PBS, containing 17.5% (w/v) Iodixanol, 0.3%
NaPTA and 0.1% (w/v) sarkosyl and centrifuged at 16100g
for 30 min. This step was repeated with the P3 pellets to
obtain the final P4 pellets. Replica P4 pellets obtained after
purification of GSS-A117V or Bv-Scr were resuspended ei-
ther in 10 ml PBS in the presence of 0.1% sarkosyl when
analysed for western blotting and bioassay analysis, or in
10 ml Tris HCl in the presence of 1 mM NaN3 and 0.1%
sarkosyl for electron microscopy analysis. A single 10-ml P4
fraction corresponded to 150 ml of the starting brain
homogenate.
To assess the infectivity of the purified fractions in relation
to the original GSS-A117V inoculum, P2 and P4 fractions
were diluted 180-fold and 360-fold in phosphate buffer, re-
spectively, to obtain an inoculum comparable with the ori-
ginal GSS+PK 4  10–3 dilution, and then serially 10-fold
diluted. SN2 supernatants, which were diluted 90-fold com-
pared to the P2 fractions, were 2-fold diluted and then seri-
ally 10-fold diluted. Two dilutions were chosen for the
titration assay: (i) the 4  10–4 dilution, to determine if the
pellets containing only purified 7 kDa PrPres aggregates were
still infectious; and (ii) the 4  10–6 dilution, to define the
correlation between PrPres amount and infectivity.
Bioassay
All animal studies were carried out in derogated CL3 facili-
ties. Bank voles were obtained from the breeding colony at
the Istituto Superiore di Sanità (ISS). Inoculated voles were
housed in autoclavable Eurostandard type II polysulphone
cages (three voles/cage) with abundant wood chips as bed-
ding material. Voles were kept under a 12-h light/dark cycle
and given food and water ad libitum. Cohorts of voles
(n = 6, 6–8 weeks of age and sex-matched) either expressing
methionine (Bv109M, inoculated with sCJD-MM1) or iso-
leucine (Bv109I, for GSS-A117V and Bv-CWD) at PrP
codon 109 were anaesthetized with ketamine (0.1 lg/g) and
inoculated with 20 ll brain homogenates or purification
fractions into the left cerebral hemisphere.
Inoculated voles were examined twice a week until the ap-
pearance of neurological signs, after which they were exam-
ined daily. Animals that died because of intercurrent disease
were excluded from the study. Diseased animals were
euthanized with CO2 at the terminal stage of the disease.
The brain from each animal was removed and cut sagittally
into two parts. One was stored at –80C and one was fixed
in formalin.
The research protocol, approved by the Italian Ministry of
Health and performed under the supervision of the Service
for Biotechnology and Animal Welfare of the ISS, adhered
to the guidelines contained in the Italian legislative Decree
116/92, which transposed the European Directive 86/609/
EEC on Laboratory Animal Protection, and then in the
Legislative Decree 26/2014, which transposed the European
Directive 2010/63/UE on Laboratory Animal Protection.
Neuropathology
Histology and immunohistochemistry were performed on
formalin-fixed tissues as previously described (Nonno et al.,


























































































2006). Briefly, brains were trimmed at standard coronal lev-
els, embedded in paraffin wax, cut at 6 mm and stained with
haematoxylin and eosin. PrP immunolabelling in immuno-
histochemistry was carried out using a mix of SAF84 and
6C2 mAbs. For the construction of lesion profiles, vacuolar
changes were scored in nine grey matter areas (Fraser and
Dickinson, 1968).
SDS-PAGE, western blot and silver
staining
Brain homogenates (10% w/v) were added with an equal
volume of 100 mM Tris HCl containing 4% sarkosyl and
incubated for 30 min at 37C with gentle shaking. PK was
added at a final concentration of 100 mg/ml and the samples
were incubated for 60 min at 55C with gentle shaking. PK
was stopped with 3 mM PMSF. Samples were added with
an equal volume of isopropanol/butanol (1:1 v/v), centri-
fuged for 10 min at 20000g and the resulting pellets were
resuspended in denaturing sample buffer (NuPAGEV
R
LDS
Sample Buffer and NuPAGEV
R
Sample Reducing Agent,
Invitrogen) and heated for 10 min at 95C.
Purified pellets were either left untreated or digested with
PK (10 mg/ml, 60 min at 55C). PMSF (3 mM) was added
to stop the digestion. Digested and untreated pellets were
mixed with an equal volume of 2 denaturing sample buf-
fer and heated at 95C for 10 min. Aliquots of the super-
natant fractions were added with an equal volume of
isopropanol/butanol (1:1 v/v), centrifuged at 20000g for 10
min and the pellets were resuspended in denaturing sample
buffer and heated at 95C for 10 min.
Electrophoresis, conducted with NuPAGEV
R
MES SDS
Running Buffer or NuPAGEV
R
MOPS SDS Running Buffer
(Invitrogen, Thermofisher) depending on the type of PrPSc
analysed, and western blotting were carried as previously
described (Pirisinu et al., 2018). The monoclonal antibodies
used and their epitopes were as follow: SAF32 (octarepeat),
9A2 (bank vole sequence amino acids 99–101), SAF60
(human sequence amino acids 157–161) and SAF84 (bank
vole sequence amino acids 163–169). Chemiluminescence
signal was detected by ChemiDoc imaging system (Bio-Rad)
and quantified using the Image Lab software (Bio-Rad).
For silver staining, SDS-PAGE gels were stained using the
PierceTM Silver Stain Kit (Thermofisher Scientific) following
the manufacturer’s instructions, and visualized with the
ChemiDoc Imaging system (Bio-Rad).
Electron microscopy
Negative staining of the purified samples was performed on
carbon-coated, 200-mesh copper grids that were previously
glow-discharged. P2 and P4 pellet fractions were resus-
pended in 10 ml Tris HCl (100 mM, pH 7.4) in the presence
of 1 mM NaN3 and 0.1% sarkosyl. Whole SN2 fractions
were added to an equal volume of isopropanol/butanol
(1:1 v/v), centrifuged at 20000g for 10 min, and the pellets
were re-suspended in 10 ml Tris-HCl (100 mM, pH 7.4) in
the presence of 1 mM NaN3 and 0.1% sarkosyl. Sample ali-
quots (5 ml) were loaded onto the grids and incubated for up
to 5 min to allow proper adsorption of the protein sample.
The grids were briefly washed with 0.1 M and 0.01 M am-
monium acetate buffer, pH 7.4 to remove surplus, non-
adsorbed protein sample and buffer and stained with two
droplets (50 ml each) of freshly filtered 2% (w/v) uranyl acet-
ate. After drying, the stained samples were viewed in a FEI
Tecnai G2 TF20 electron microscope (FEI company) at an
acceleration voltage of 200 kV. Each grid was analysed
systematically using the tracking feature of the CompuStage
(FEI Company) to determine the ultrastructure of the
adsorbed sample. The recorded tracks allowed a wide-
ranging, non-overlapping search pattern that covered most
of the grid surface. This systematic surveying approach
allowed us to ascertain the aggregation state of the adsorbed
sample. Images were recorded on an Eagle 4k  4k multi-
port CCD camera (FEI company) with a 4-port readout and
a 14  14 mm2 physical pixel size.
Immunogold labelling
Fab 69 was selected from a phage display library for its abil-
ity to bind murine PrP (Senatore et al., 2020). For the immu-
nogold labelling experiments Fab 69’s ability to recognize an
epitope within residues 87GWGQGGGTHNQW98 of murine
PrP was essential as this epitope is retained in the 7 kDa
PrPres fragments. Fab 69 was expressed in Escherichia coli
[BL21(DE3)] as a His-tagged, soluble, and functional pro-
tein. Upon lysis of the bacterial cells, Fab 69 was purified
via IMAC chromatography, eluted using imidazole buffer,
desalted, and characterized for its purity and activity
(Rathod et al., unpublished data).
The immunogold labelling protocol was adapted from
Wille et al. (2007): 2–3 ll samples were absorbed for 6 min
onto glow-discharged formvar/carbon-coated nickel
grids (Ted Pella, Inc.). The grids were then washed with
50 ll 0.1 M and 0.01 M ammonium acetate buffer pH 7.4
and treated with 50 ll of 3 M urea for 10 min, which served
to increase the accessibility of the epitope that is recognized
by Fab 69. After washing with 50 ll of the 0.1 M and 0.01
M ammonium acetate buffers, the grids were pre-stained
with 2% phosphotungstate, pH 7.2 (PTA). The formvar/car-
bon-film surface was then blocked for 60–90 min with
0.3% bovine serum albumin (BSA) in Tris-buffered saline
(TBS: 50 mM Tris HCl, pH 7.4; 150 mM NaCl), incubated
with the primary antibody (Fab 69) for 3 h, rinsed five times
with 0.1% BSA in TBS, incubated with a bridging goat
F(ab0)2 anti-human IgG F(ab0)2 (Abcam ab98531) for 2 h,
rinsed five times again with 0.1% BSA in TBS, incubated
with a 5-nm gold-conjugated rabbit anti-goat IgG (Abcam
ab202670) for 2 h, rinsed five times with 0.1% BSA in TBS,
twice with TBS alone, and twice with water. Controls were
treated identically, except that the primary Fab was omitted.
Finally, the grids were counterstained twice with 50 ll 2%
PTA and air-dried. The dried grids were analysed using a
Tecnai G2 TF20 electron microscope (FEI company), as


























































































described. Gold particles that were observed within a radius
of 25 nm from a structure of interest were considered specif-
ically bound, since the length of a Fab molecule is 5 nm
while that of an IgG is 10 nm (5 nm primary Fab + 5 nm
bridging Fab + 10 nm IgG + 5 nm gold particle diameter =
25 nm). Gold particles that exceeded this 25 nm distance
threshold were deemed non-specific background labelling.
Data availability
The authors confirm that the data supporting the findings of
this study are available within the article and its
Supplementary material.
Results
PK-treated GSS-A117V retains full
infectivity
In a previous study, we demonstrated that GSS cases with
only 7 kDa PrPres are experimentally transmissible in voles
(Pirisinu et al., 2016), suggesting that infectivity could be
associated with the 7 kDa PK-resistant core of PrPSc.
However, those data could not exclude that other PrPSc con-
formers, sensitive to proteases, might have played a role in
the observed phenotypes. To solve this issue, we sought to
determine if prion infectivity associated with atypical PrPSc is
resistant to PK, which is known to cleave both the N- and
C-termini of atypical PrPSc. To this aim, we end-point
titrated prion isolates from a GSS-A117V case (GSS-A117V
#1) in bank voles, as a model for atypical PrPSc, and from
two prion diseases associated with classical PrPSc, i.e. sCJD-
MM1 and bank vole adapted CWD (Bv-CWD). GSS-
A117V and Bv-CWD were chosen for their ease of transmis-
sion into bank voles carrying isoleucine at position 109
(Bv109I) (Di Bari et al., 2013; Pirisinu et al., 2016) and
were thus titrated in Bv109I. In contrast, sCJD-MM1 was
assayed in bank voles carrying methionine at codon 109
(Bv109M), which replicate this strain faster than Bv109I
(Nonno et al., 2006; Rossi et al., 2017). Brain homogenates
from the three cases were either left untreated or digested
with PK at a concentration that allowed the complete deg-
radation of PrPC, serially diluted 10-fold and inoculated in
voles. Upon PK digestion, only PrPres species were detected
in the inocula. The PK-treated GSS-A117V sample only
showed N- and C-terminally truncated, unglycosylated
PrPres of 7 kDa (Fig. 1). Faint PrPres fragments of 14 kDa
and 21 kDa shared the same antibody reactivity as 7 kDa
PrPres and likely represent its covalently linked multimers, as
reported in previous studies (Pirisinu et al., 2013; Cracco
et al., 2019). The N-terminally truncated, fully glycosylated
PrPres types, with protease-resistant unglycosylated frag-
ments of 19 kDa for Bv-CWD and of 21 and 14 kDa for
sCJD-MM1, were detected in PK-treated Bv-CWD and
sCJD samples instead (Fig. 1).
As expected, PK treatment did not substantially affect the
infectivity titre of the two classical prion diseases
(Supplementary Table 1). Indeed, sCJD-MM1 showed
ID50 U/g values of 10
5.6 when untreated and 106.1 with PK
treatment, while ID50 U/g values of 10
8.4 and 108.1 were
observed for untreated and PK-treated Bv-CWD, respective-
ly. Unexpectedly, GSS-A117V showed an extremely high in-
fectious titre in voles, even higher than classical prions, with
an ID50 U/g value of 10
9.3 for the GSS untreated inoculum.
Moreover, the infectious titre was not substantially altered
upon PK treatment, with the PK-treated GSS-A117V inocu-
lum showing an ID50 U/g value of 10
9.0 (Supplementary
Table 1). As previously reported (Nonno et al., 2006; Di
Bari et al., 2013; Pirisinu et al., 2016), voles infected with
GSS-A117V, sCJD-MM1 and Bv-CWD reproduced distinct-
ive neuropathological patterns and PrPSc types, suggestive of
the isolation of three distinct vole-adapted strains
(Supplementary Figs 1 and 2). Most importantly, these phe-
notypes were unchanged in voles inoculated with PK-treated
samples, suggesting that PK-resistant molecules retain the
strain properties in these TSEs, including atypical GSS-
A117V (Supplementary Figs 1 and 2). Interestingly, the se-
verity of spongiosis in the cerebellum of voles infected with
GSS-A117V varied according to the dilution of the inocu-
lum, independently of the PK pretreatment of the inoculum
(Supplementary Fig. 2).
Overall, these results establish that GSS-A117V contains
PK-resistant and strain-specific prions, similar to prion dis-
eases associated with classical PrPSc.
Purified 7 kDa PrPres aggregates
retain prion infectivity and strain
properties
The outcome of the previous experiment strongly suggested
that the 7 kDa PrPres aggregates that remained after PK di-
gestion are responsible for the infectivity and the strain fea-
tures of GSS-A117V. To definitely demonstrate a direct
association between infectivity and 7 kDa PrPres we decided
to isolate these PrPres aggregates in order to obtain pure
preparations of in vivo generated prions.
To this aim, we used a novel purification method for
obtaining highly enriched pure prion preparations recently
developed for mouse scrapie prions (Wenborn et al., 2015).
In this method, an initial treatment with PE, which preserves
the PK-sensitive N-terminus of classical PrPSc, allows the
purification of full-length PrPSc that can then be N-terminal-
ly truncated into PrPres upon PK treatment.
We first used this method to purify classical PrPSc from
the brains of scrapie affected bank voles (Bv-Scr). We
obtained a first semi-purified pellet fraction, i.e. P2, con-
taining full-length PrPSc, with intact C- and N-termini
(Fig. 2). The semi-purified PrPSc obtained in P2 was par-
tially resistant to PK, which cleaved the N-terminus lead-
ing to the typical three bands PrPres pattern of classical
scrapie in western blot (Fig. 2). The PrPres amount


























































































obtained in the P2 pellet, determined by chemiluminescent
signal, was about three times lower than the quantity of
PrPres present in the starting brain homogenate
(Supplementary Fig. 3). While attempting to purify PrPSc
from GSS-A117V we found that, in contrast to classical
PrPSc, the C-terminus of atypical PrPSc was PE-
sensitive (Fig. 2), confirming that the C-terminus of atyp-
ical PrPSc has a distinct structure and is accessible to pro-
teases. Thus, the semi-purified P2 fraction that we
obtained from GSS-A117V #1, named PE_P2, did not con-
tain full-length PrPSc but C-terminally cleaved PrPSc.
Interestingly, the N-terminus of atypical PrPSc was partial-
ly preserved upon PE treatment, as confirmed by the weak
signal detected in western blot with the antibody SAF32
(Fig. 2). Similar to classical PrPSc, semi-purified GSS-
A117V PrPSc from the PE_P2 pellet was partially resistant
to PK, which removed the remaining N-terminus thus
resulting in the 7 kDa PrPres aggregates that we sought to
purify.
However, the recovery of PrPres in the P2 fraction was
lower than that observed with classical PrPSc, with PrPres in
the PE_P2 pellet being 10 times less than in the original
brain homogenate (Supplementary Fig. 3).
In an attempt to increase the yield of 7 kDa PrPres in the
P2 fraction, we replaced PE treatment with PK treatment.
We obtained a P2 fraction, i.e. PK_P2, containing only the
7 kDa N- and C-termini cleaved PrPres (Fig. 2). Again, the
PK_P2 fraction contained 10 times less PrPres than the
starting brain homogenate.
To investigate the reason for the low PrPres yield in the
GSS-A117V P2 pellets, we analysed the amount of PrPres in
all fractions of both Bv-Scr and GSS-A117V samples. Bv-Scr
and GSS-A117V had a comparable recovery of PrPres after
the first centrifugation, i.e. in the supernatant fraction SN1,
but their behaviour was different during the centrifugation
in 17.5% iodixanol, which allowed the separation of the
sample into an insoluble pellet P2 and a soluble supernatant
SN2. Indeed, as expected, classical PrPres was highly
enriched in the P2 fraction and partitioned into SN2 and P2
at a ratio of 1:3, respectively, indicating that only a small
amount of PrPres remained in the supernatant fraction. By
contrast, most of the 7 kDa PrPres was retained in the SN2
fraction, with a SN2: P2 distribution of 2:1, indicating
that under those conditions of centrifugation, the 7 kDa
PrPres did not sediment efficiently, thus explaining the low
amount of PrPres in the P2 fraction (Fig. 3).
The inefficient sedimentation observed with the 7 kDa
PrPres means that the atypical PrPSc is characterized by sedi-
mentation properties different from those of classical PrPSc,
suggesting that this PrPSc type might predominantly consist
of small-sized/low density aggregates.
We then aimed at evaluating the infectivity of the purified
fractions containing 7 kDa PrPres. PE_P2 and PK_P2 GSS-
A117V pellets were diluted 1800 and 180000-fold in
Figure 1 PrP species in PK-treated and untreated inocula. Total PrP (first lane of each blot) and PrPres (second lane of each blot) in brain
homogenates from GSS-A117V, sCJD-MM1 and Bv-CWD were analysed by western blot using monoclonal antibodies directed to the central re-
gion (9A2) or the C-terminus (SAF60 and SAF84 for human and bank vole PrP, respectively) of PrP. The second lane of each blot was duplicated
as a schematic and added on the right of the blot to better illustrate the PrPres electrophoretic pattern of the PK-treated samples analysed; the
size of each rectangle represents the amount of chemiluminescent signal of the respective PrPres fragment in the blot. The PK-treated GSS-
A117V inoculum was characterized by 7 kDa PrPres devoid the C-terminus of the protein, as it is recognized by the internal antibody 9A2 but
not by the C-terminal antibody SAF60 (larger rectangle in the 9A2 schematic box). Note the presence of multimers of 7 kDa PrPres (higher mo-
lecular weight bands of 14 and 21 kDa, represented by the thinner rectangles in the 9A2 schematic box), which share the same antibody re-
activity of the 7 kDa PrPres, i.e. they are recognized by the internal antibody but not by the C-terminal one. The PK-treated sCJD-MM1 inoculum
was characterized by a complex PrPres pattern, resulting from the overlapping of (i) type 1 PrPres, recognized by both the antibodies (three dark
grey rectangles in both the schematic boxes), which is characterized by a dominance of the mono-glycosylated fragment, with an unglycosyilated
fragment of 21 kDa in size; (ii) an additional C-terminal, fully glycosylated PrPres fragment that is recognized only by the C-terminal antibody
(SAF60, three light grey rectangles in the SAF60 cartoon box), with an unglycosylated fragment of 14 kDa in size. The PrPres in the Bv-CWD in-
oculum was instead characterized by a classical PrPres pattern with an unglycosylated fragment of 19 kDa in size and a dominance of the di-glyco-
sylated fragment (9A2 and SAF84, three dark grey rectangles in both the schematic boxes). The asterisks indicate non-specific bands detected in
untreated brain homogenates by the antibody 9A2.


























































































phosphate buffer, respectively, to obtain dilutions equivalent
to the 4  10–4 g/ml and 4  10–6 g/ml of the brain hom-
ogenate dilutions used in the titration of the original GSS-
A117V sample. These preparations were used to inoculate
voles, along with the 4  10–4 g/ml dilutions of a P2 purified
fraction derived from uninfected vole brain tissue as a nega-
tive control (Bv-Neg), and of the original untreated GSS-
A117V sample as a positive control (Table 1).
Remarkably, all voles inoculated with the dilution
4  10–4 g/ml of the PE_P2 and PK_P2 pellets became clin-
ically sick, confirming that the human-derived purified 7
kDa PrPres aggregates are fully infectious in voles. Infectivity
was still detectable in the 4  10–6 g/ml dilution, i.e. after
a4100000-fold dilution of the P2 pellet fraction, although
both PE_P2 and PK_P2 showed a partial attack rate at this
dilution, comparable to the outcome of the 4  10–8 g/ml
dilution of the PK-treated GSS-A117V brain homogenate
(see Supplementary Table 1 for comparison). This allows us
to conclude that the P2 pellets contained comparable levels
of infectivity, being both 100-fold less infectious than the
original GSS-A117V inoculum, in keeping with the low re-
covery of the 7 kDa PrPres during the purification.
Interestingly, no difference in terms of infectivity was
observed between the PE and PK-treated pellets, indicating
that the octarepeat region of PrP that is partially preserved
upon PE treatment does not play a significant role in prion
infectivity. In agreement with these conclusions, the purified
PE_P2 fraction preserved infectivity after a further PK treat-
ment (referred to as PE_P2_PK in Table 1).
As SN2 fractions contained higher amounts of 7 kDa
PrPres than the P2 fractions (Fig. 3), we aimed at determining
if this correlated with higher levels of infectivity, i.e. if the
distribution of infectivity in the SN2/P2 separation correlated
with the distribution of PrPres, by inoculating voles with
PE_SN2 and PK_SN2, both equivalently diluted to the
4  10–4 g/ml and 4  10–6 g/ml of the brain homogenate
dilutions. Indeed, the two supernatants PE_SN2 and
PK_SN2 contained higher levels of infectivity than the corre-
sponding P2 fractions, resulting in 100% attack rates at
both dilutions (Table 1).
Finally, the analysis of the PrPres type and of the neuro-
pathological phenotype in voles inoculated with the different
fractions confirmed that the original GSS-A117V strain fea-
tures were preserved in all fractions and were identical to
those of the original inoculum (Fig. 4 and Supplementary
Figs 4–6). The slight variation of the degree of spongiosis in
the cerebellum of voles inoculated with SN2 and P2 frac-
tions (Supplementary Fig. 6) was reminiscent of that
observed in the titration experiment (Supplementary Fig. 2)
Figure 2 PrPSc in the purified fractions from scrapie and
GSS-A117V. P2 pellets obtained from scrapie affected voles (Bv-
Scr) (A) or GSS-A117V (B) with the purification methods using PE
(PE_P2) or PK (PK_P2) as proteases, were analysed by western
blot either untreated (–) or subjected to a further PK digestion
( + ). The PE_P2 fraction from Bv-Scr contained full-length PrPSc
that upon PK digestion showed the typical three band PrPres pat-
tern. In contrast, the GSS-A117V PE_P2 fraction contained low mo-
lecular weight C-terminal cleaved PrPSc fragments, not detected by
the C-terminal antibody SAF60, but partially preserving the octare-
peat region in the N-terminus (detected with SAF32). Upon PK di-
gestion of PE_P2 from GSS-A117V, PrPres was only detected with
antibody 9A2, revealing the expected 7 kDa PrPres profile, devoid
of both the N- and C-terminus. The GSS-A117V PK_P2 pellet con-
tained only 7 kDa PrPres, already devoid of N-terminal and C-ter-
minal moieties, as it was only detected by the internal antibody
9A2.
Figure 3 Comparison of PrPres in SN2 and P2 fractions.
SN2 (PE_SN2) and P2 (PE_P2) fractions obtained from scrapie
affected vole (Bv-Scr) (A) or from GSS-A117V (B) were treated
with PK ( + ) and analysed by western blot with antibody 9A2. For
GSS-A117V, SN2 and P2 fractions obtained with the purification
protocol using PK as protease (PK_SN2 and PK_P2, respectively)
were also analysed. PrPres was mainly enriched in the P2 fraction in
Bv-Scr (A), while it was mainly detected in SN2 fractions from GSS-
A117V (B). Note that no difference in terms of SN2/P2 partitioning
was observed using PE or PK during the purification method. All
membranes were detected with antibody 9A2.


























































































and was probably due to the different dilutions and levels of
infectivity in SN2 and P2 fractions.
Overall, these findings imply that PrPres aggregates com-
posed of only N- and C-terminally truncated 7 kDa PrPres,
purified from a human brain affected with the prion disease
GSS-A117V, are fully infectious prions and encode the strain
features of the original full-length PrPSc molecule.
Furthermore, our results clearly demonstrate that infectivity
correlates directly with the 7 kDa PrPres, as it decreases at
the same rate as the amount of PrPres in the inoculum.
Purified prions from GSS-A117V
are small non-fibrillar particles
A crucial question in the prion field is the 3D structure of
the infectious PrPSc conformer, but the experimental
obstacles posed by the highly aggregated, glycosylated, and
GPI-anchored conventional PrPSc conformers, and the diffi-
culties of obtaining highly infectious synthetic prions, present
formidable obstacles (Wille and Requena, 2018). In this con-
text, purified 7 kDa PrPres aggregates, associated with high
levels of infectivity and made up of short, non-glycosylated
and non-GPI-anchored PrP fragments, might potentially
overcome these obstacles and could be exploited for struc-
tural studies.
To obtain highly purified preparations void of contaminat-
ing proteins and suitable for analysis by electron micros-
copy, we added two further centrifugation steps to the
whole purification method, resulting in pure P4 pellets. We
thus generated purified 7 kDa PrPres samples from two unre-
lated GSS-A117V cases (named GSS-A117V #1, previously
used for the titration assay and the first analysis of purified
7 kDa PrPres, and GSS-A117V #2) and equivalent 20 kDa
PrPres from Bv-Scr. The final pure PK_P4 pellet from Bv-Scr
contained similar amounts of PrPres than the PK_P2 fraction,
with all major SDS-PAGE silver stained bands overlapping
with the bands recognized by the anti-PrP antibody on west-
ern blot (Fig. 5). P4 pellets derived from GSS-A117V #1 and
GSS-A117V #2 showed comparable or slightly lower (GSS-
A117V #1) levels of PrPres than the corresponding P2 pellets,
although unrelated proteins still present in the P2 fractions
were absent in P4. Thus, the major SDS-PAGE silver stained
band in GSS-A117V P4 pellet overlapped with the 7 kDa
band recognized by the anti-PrP antibody on western blot
(Fig. 5). Most importantly, infectivity co-segregated with
PrPres aggregates, as P4 from Case 1 was still infectious after
3600-fold dilution (equivalent to the 4  10–4 g/ml of the
brain homogenate) (Table 1). Still, the infectious titre was
lower in P4 than in P2 (compare the 4  10–6 g/ml dilutions
Table 1 Transmission in bank voles of purified fractions of PrPSd from GSS-A177V
Inoculum Status Fraction 4 3 10–4 g/mla 4 3 10–6 g/mla
Attack rate, n/Nb Survival time ± SD, daysc Attack rate, n/Nb Survival time ± SD, daysc
GSS-A117V Supernatant PE_SN2 5/5 112 ± 6 6/6 143 ± 39
GSS-A117V Pellet PE_P2 6/6 136 ± 3 2/6 183 ± 7
GSS-A117V Pellet PE_P2_PK 6/6 124 ± 11 nd nd
GSS-A117V Supernatant PK_SN2 5/5 103 ± 4 6/6 113 ± 13
GSS-A117V Pellet PK_P2 5/5 120 ± 11 3/6 142 ± 7
GSS-A117V Pellet PK_P4 5/5 149 ± 12 0/7 4350
Bv-Neg Pellet PK_P2 0/4 4350 nd nd
GSS-A117V BHd – 4/4 112 ± 12 nd nd
SD = standard deviation; n = number of voles that developed confirmed TSE disease; N = number of inoculated mice; nd = not done.
aPurified fractions from GSS-A117V #1 were diluted to reach dilutions equivalent to the 4  10–4 g/ml and 4  10–6 g/ml dilutions of the starting brain homogenate, as reported in
the ‘Materials and methods’ section.
bVoles dead from intercurrent disease were excluded from the study.
cWhen voles did not show clinical signs, the time of the last animal of the group tested negative was reported.
dUntreated GSS-A117V #1 brain homogenate (BH) diluted and used as positive control.
Figure 4 PrPSc and spongiform degeneration in voles
inoculated with supernatant and pellet fractions from
GSS-A117V. (A) Representative western blot of PrPres from voles
inoculated with the original brain homogenate (untreated BH) or
with supernatant (PE_SN2 or PK_SN2) and pellet (PE_P2 or
PK_P2) fractions from GSS-A117V. Membranes were probed with
antibody 9A2. (B) Patterns of neurodegeneration analysed by semi-
quantitative assessment of spongiform degeneration in different
brain regions (lesion profiles) of voles inoculated with the untreated
brain homogenate or with the different purification fractions from
GSS-A117V, as indicated at the top of the graph. Brain scoring areas
are: medulla (1), cerebellum (2), superior colliculus (3), hypothal-
amus (4), thalamus (5), hippocampus (6), septum (7), retrosplenial
and adjacent motor cortex (8), cingulate and adjacent motor cortex
(9). Each point represents the mean ± standard error of the mean
(SEM) of at least four individual voles.


























































































of PK_P2 and PK_P4 in Table 1), in keeping with the lower
PrPres content in P4 (Fig. 5).
Ultrastructural analyses using negative stain electron mi-
croscopy of PK_P2 and PK_P4 samples from scrapie-affected
vole brains that contain only classical PrPres revealed the
presence of clumps of amyloid fibrils (Fig. 6B), morphologic-
ally similar to those observed in other classical prion strains
(Wenborn et al., 2015). In sharp contrast, PK_P2 and
PK_P4 pellets generated from the two GSS-A117V cases
showed no fibrils at all; instead, they contained very small
and structurally indistinct particles that covered the grid sur-
face, with occasional lipid and amorphous
structures (Fig. 6A). The alcohol precipitates of all samples
contained only amorphous aggregates, as expected for
alcohol-treated samples.
To ascertain the nature of the structurally indistinct par-
ticles in the PK_P2 and PK_P4 pellets, we conducted immu-
nogold labelling experiments with a recombinantly produced
antibody fragment (Fab 69) that recognizes an epitope near
the N-terminus of the 7 kDa fragment (Fig. 7). Using a bin-
ary system to detect bound Fab 69 we were able to decorate
the small, 7 kDa fragment particles with 5 nm gold labels
(Fig. 7A), while a control sample for which the primary Fab
was omitted showed only a few gold particles as unspecific
background labelling. Similarly, the amyloid fibrils in the
Bv-Scr PK_P2 samples were recognized by Fab 69 and
decorated with 5-nm gold labels (Fig. 7B), while the amyloid
fibrils in the controls (no primary Fab) remained undecor-
ated. Lastly, bank vole brains from uninfected animals that
were subjected to the same purification procedure, resulting
in PK_P2 control samples (Bv-Neg), revealed only a few, un-
specific gold labels independent of the presence or absence
of Fab 69 (Fig. 7C). Therefore, the immunogold labelling
experiments confirmed that the observed, structurally indis-
tinct oligomeric particles (Fig. 6A) contain a PrP epitope be-
tween residues 87 and 98.
Figure 5 Purified PrPres from Bv-Scr and human GSS-
A117V isolates. P2 and P4 fractions obtained with the PK purifi-
cation method from Bv-Scr (A) and from two GSS-A117V cases,
indicated as GSS-A117V #1 and #2 (B), were analysed by western
blot (WB) and silver staining to evaluate the presence and purity of
PrPres. Fractions were loaded at 1.5 mg equivalent for western blot
analysis and at 10 mg equivalent for silver staining. Blots were
probed with antibody 9A2; SDS gels were used for the silver stain-
ing as indicated in the ‘Materials and methods’ section. Arrows on
the right of silver-stained P4 fractions indicate the major SDS-PAGE
silver-stained bands, which were consistent with PrPres detected
with 9A2 by western blot. Asterisks indicate protein bands
detected in the P2 fractions of both Bv-Scr and GSS-A117V that
were absent in P4 pellets.
Figure 6 Negative stain electron micrographs from human
GSS-A117V and Bv-Scr isolates. The P2 and P4 fractions from
the GSS-A117V isolates (A) and Bv-Scr (B) as well as the corre-
sponding SN2 fractions (after alcohol precipitation) were negatively
stained with uranyl acetate. The P2 and P4 fractions from the GSS-
A117V isolates (A) contained a layer of small amorphous particles
that covered the carbon film surface (filled arrowheads on select
particles). No amyloid fibrils or larger protein aggregates were
observed, occasional lipid structures and amorphous structures
were visualized (black arrows). The SN2 precipitate was comprised
of amorphous aggregates only (white arrows), which is typical for
alcohol precipitates. In contrast, the P2 and P4 fractions from Bv-
Scr (B) contained substantial quantities of amyloid fibrils (black
dashed arrows), which tended to aggregate into larger clumps, par-
tially obscuring their ultrastructure. The SN2 precipitate again
showed only amorphous structures (white arrows) because of the
alcohol treatment. Scale bars = 100 nm.



























































































Experimental evidence that GSS subtypes, which are ex-
clusively associated with 6–8 kDa PrPres fragments, repre-
sent genuine prion diseases has recently been reported
(Asante et al., 2013; Pirisinu et al., 2016). However, a
direct association between low molecular weight, non-gly-
cosylated, and non GPI-anchored PrPres fragments and in-
fectivity was still missing. Indeed, even if 7 kDa PrP
peptides had been reported as components of the amyloid
plaques in the brains of GSS-A117V patients (Tagliavini
et al., 2001), their role in the pathogenesis of the disease
and in the propagation of infectious conformation
remained elusive.
We discovered that GSS-A117V brain tissues are charac-
terized by an extremely high infectious titre when inoculated
in voles. Moreover, the PK-treated inoculum, which con-
tained the 7 kDa PK-resistant PrP fragment, was character-
ized by the same level of infectivity as the untreated
inoculum, which was composed of full-length PrPSc and PK-
sensitive PrP isoforms. These findings allow us to conclude
that, as for prion diseases associated with classical PrPSc, the
infectivity of GSS-A117V is resistant to PK and is not associ-
ated with PK-sensitive forms of PrP. While this finding clear-
ly suggested a correlation between 7 kDa PrPres aggregates
and infectivity, a definitive proof of the infectious nature of
the 7 kDa PrPres aggregates could only be achieved via puri-
fication of these atypical PrPres aggregates. Indeed, we found
that purified, patient-derived 7 kDa PrPres aggregates are in-
fectious in voles and faithfully transmit the strain features of
the initial GSS-A117V brain inoculum. The specific infec-
tious role of 7 kDa PrPres aggregates was demonstrated by
the co-segregation of infectivity and PrPres in the purified P4
fraction and was further corroborated by the parallel de-
crease of infectivity and PrPres during purification, which fol-
lowed the same rank order BH 4 SN24 P24 P4. Thus,
PrPres aggregates that contain PrP-derived peptides encom-
passing residues 90–150 are sufficient as GSS prions and
encode their strain properties. As similar 90–150 PrP pep-
tides are formed in vivo and can be extracted from amyloid
plaques of GSS-A117V patient brains (Tagliavini et al.,
2001), it is conceivable that aggregates of misfolded
90–150 PrP fragments play a fundamental role in the
autocatalytic propagation of the disease and could represent
an important therapeutic target to slow the progression of
the disease.
Besides the above-mentioned implications for better under-
standing the pathogenesis of GSS-A117V disease, our find-
ings also provide new insights into the structural
determinants of prion infectivity. We have demonstrated
that human-derived small PrP peptides, devoid of Asn-linked
glycans and GPI-anchor moieties, are able to interact with
host PrPC and to catalyse its misfolding into a pathogenic
and autocatalytic replicating conformation. These findings
demonstrate that the misfolded conformation of 90–150
PrP peptides contains the key elements sufficient to encode
for GSS-A117V prions and imply that the C-terminus of
PrP, along with its Asn-linked glycans and the GPI-anchor,
are dispensable for the structure of a prion. The latter con-
clusion is supported by several studies showing prion infect-
ivity associated with in vitro misfolded recombinant PrP,
which lacks all post-translational modifications (Legname
et al., 2004; Wang et al., 2010), and with misfolded N- and/
Figure 7 Immunogold labelling of human GSS-A117V, Bv-
Scr, and Bv-Neg isolates. The P2 fractions from GSS-A117V
(A), Bv-Scr (B), as well as Bv-Neg isolates (C) were used for immu-
nogold labelling experiments with an anti-PrP Fab (Fab 69), which
recognizes an epitope between residues 87 and 98. The small
amorphous particles in the GSS-A117V isolate were decorated
with many 5 nm gold particles, while a sample that was treated
identically except for the omission of the primary Fab showed only
one gold particle (filled arrowhead). Because of the size and nature
of the GSS-A117V particles, the attached gold labels cannot be
assigned to specific particles. The amyloid fibrils in the Bv-Scr iso-
late (B) were decorated with gold particles indicating that they are
composed of PrP, while in the control sample without primary Fab
the fibrils remained undecorated. A gold particle that is too far
from the amyloid fibrils represents non-specific background label-
ling (filled arrowhead). Bv-Neg samples (C) that lack PK-resistant
PrP only showed low levels of background labelling as indicated by
individual gold particles (filled arrowheads). Scale bars = 100 nm.


























































































or C-terminally truncated recombinant PrP (Kaneko et al.,
2000; Choi et al., 2016).
Although 7 kDa PrPres aggregates do not contain covalently
linked glycans or a GPI anchor, our results do not exclude
that other brain-derived molecules might be integral compo-
nents of purified 7 kDa PrPres. The need for co-factors as an
integral component of highly infectious prions is a matter of
intense investigation (Wang et al., 2010; Deleault et al., 2012;
Supattapone, 2014). Recent evidence suggests that pure
preparations of recombinant PrPSc without co-factors may
be infectious for wild-type mice (Choi et al., 2016) and
bank voles (Fernández-Borges et al., 2018). It is note-
worthy that, in both these studies, recombinant prions
induced atypical, C-terminally truncated PrPres in the re-
cipient rodents, similar to what was observed in the present
study using Bv109I inoculated with purified GSS-A117V 7
kDa PrPres.
Usually, a PK-resistant core spanning residues 90–231
characterizes infectious PrPSc. Studies with recombinant PrP
have shown that PrP conformers with a shorter, C-terminal
PK-resistant core encompassing residues 160–231 are not
infectious (Makarava et al., 2011; Zhang et al., 2014;
Groveman et al., 2015). We have recently found that a
brain-derived PrPSc conformer with an unusual C-terminal
PrPres, which does not include the central PrP domain 90–
150, behaves as a ‘defective prion’, competent for autocata-
lytic self-propagation in vitro but unable to propagate
in vivo (Vanni et al., 2016), and PrPSc aggregates lacking the
central polybasic domain showed comparable behaviour
(Miller et al., 2011). Moreover, this central PrP domain con-
tains the polybasic lysine cluster that has been indicated as a
key structural determinant for PrPC-to-PrPSc conversion.
Overall, these studies strongly suggest that the central
90–150 PrP domain might be an obligate component of
the PK-resistant core of infectious prions. Conversely, an ob-
vious consequence of the present study is that the C-terminal
region of PrPSc, i.e. from residue 150 up to the C-terminus,
is not necessary for infectivity. Taken together, these findings
support the view that the PrP region spanning residues
90–150 is the minimal PrPSc component, which allows a
level of structural complexity that is able to support self-rep-
lication of prions.
X-ray fibre diffraction of PrPSc and PrPres fibrils as well as
cryo-electron microscopy analyses of GPI-anchorless PrPres
fibrils independently indicated a four-rung b-solenoid struc-
ture as the key feature of the infectious conformer (Wille
et al., 2009; Vázquez-Fernández et al., 2016). These findings
suggested a more general role for the four-rung b-solenoid
structure in the autocatalytic propagation mechanism that
characterizes prions (Wille and Requena, 2018). However,
the residue 90–150 minimal PrPSc component responsible
for the infectivity of GSS-A117V is too small to account for
a four-rung b-solenoid structure, thus suggesting that an al-
ternative structural arrangement must account for the
observed self-replication of the 7 kDa PrPres aggregates,
which could entail a two-rung b-solenoid configuration.
Indeed, it has been shown by X-ray fibre diffraction that the
synthetic peptide PrP(89–143, P101L) supports both a two-
rung solenoidal architecture and a stacked-sheet structure,
depending on the conditions of amyloid formation (Wan
et al., 2015). Finally, solid-state nuclear magnetic resonance
studies of infectious PrP23-144 fibrils showed that its short
b-sheet core (residues 112–139) was characterized by a
parallel in-register organization of b-strands (Helmus et al.,
2011).
The present study provides the biochemically simplest,
highly infectious PrPSc prions ever purified from diseased
brains, and our findings provide new constraints for studies
aimed at investigating the structure of prions. The ability to
unequivocally correlate infectivity with a known 3D struc-
ture is the necessary basis for understanding the molecular
underpinnings of prion infectivity. Recent studies have
shown that prions purified from multiple scrapie strains con-
tain PrPSc that is assembled into rod-like assemblies, referred
to as prion rods, with a common hierarchical assembly con-
sisting of twisted pairs of short fibres with a repeating sub-
structure (Terry et al., 2016; Vázquez-Fernández et al.,
2016). In this scenario, one unexpected finding of our study
was that GSS-A117V infectivity, although purified using the
same purification protocol that allowed the direct associ-
ation of infectivity with prion rods and fibrils (Wenborn
et al., 2015; Terry et al., 2016), was instead associated with
small oligomeric assemblies, and not with the commonly
observed, larger fibrillar structures or prion rods.
Although unexpected, the non-fibrillar nature of GSS-
A117V prion particles is in agreement with the relatively
low amount of PrP monomers in our preparations compared
to their high infectious titre, which correlates with the pres-
ence of numerous small oligomers versus only few prion
rods. Moreover, this finding is also in agreement with the
observed lower sedimentation rate of 7 kDa PrPres compared
to the fibrillar PrPSc aggregates, which characterize classical
scrapie prions. Lastly, these observations imply that a fibril-
lar quaternary structure is not an absolute requirement for
prion infectivity, as had been seen with the complete lack of
fibrillar assemblies in RML-infected FVB mice (Godsave
et al., 2008, 2013; Levine et al., 2015).
Our findings are in line with a proposed key role of
PrPSc oligomers in the propagation of prion disorders as it
has been shown that prion infectivity distributes widely
when fractionated in density gradients and that smaller
particles appear to account for a substantial proportion of
the total infectivity in brain homogenates (Silveira et al.,
2005; Tixador et al., 2010; Kim et al., 2012; Laferrière
et al., 2013). The fractionation of purified prions by
sonication and detergents led to the identification of non-
fibrillar oligomers of PrP, with masses equivalent to 14–
28 PrP molecules, as the most infectious prion particles
(Silveira et al., 2005). Both small and large PrPSc aggre-
gates could contribute to disease pathogenesis, accounting
in variable proportions for propagation and resistance in
the host environment. Long-range interactions in large fi-
brillar infectious aggregates might confer high resistance
in the host environment, while smaller oligomers are


























































































considered metastable intermediates to fibril formation or
an off-pathway product of aggregation. Our findings chal-
lenge this view, in that we found only small amorphous
PrPSc particles in GSS-A117V, but not larger fibrils, sug-
gesting that these small particles are stable and could rep-
resent the best compromise between stability and
infectivity of PrPSc in GSS-A117V. It could be hypothe-
sized that the A117V pathogenic mutation in PrP confers
stability to oligomers, while oligomers of wild-type human
PrP would be only transient and progress towards a rapid
structural transition to fibrils. Consistent with this hy-
pothesis, molecular simulation studies with PrP model
peptides showed that the A117V substitution enhanced
the population of b-hairpin peptides that form oligomers
and slowed the formation of fibrils once nucleation had
occurred (Gill, 2014). An alternative hypothesis is that the
absence of the C-terminus in 7 kDa PrPres aggregates plays
a role in stabilizing PrPSc oligomers or in preventing their
structural reorganization into fibrils.
Although purified amyloid proteins usually consist of
large aggregates with a fibrillar quaternary structure, non-
fibrillar oligomers have been observed for a number of
amyloid proteins associated with neurodegeneration, such
as amyloid-b, tau and a-synuclein. Accumulating evidence
in the past two decades suggests that these oligomers are
likely the most toxic species in Alzheimer’s, Parkinson’s
and other neurodegenerative diseases (Haass et al., 2012;
Kayed and Lasagna-Reeves, 2013; Forloni et al., 2016;
Shafiei et al., 2017). The structural relationship between
small-sized infectious particles in brain homogenate with
that of the larger purified fibrils is still debated. A major
obstacle to understanding this relationship has been the
transient nature of oligomers, which prevented to date
high resolution structural characterization of in vivo
derived oligomers. Our findings that PrPSc oligomers can
be purified from GSS-A117V provide a new tool to under-
stand the molecular organization of PrPSc, also in light of
the simplified biochemical composition of 7 kDa PrPres.
The high resolution structure of the GSS-A117V PrPSc
oligomers would thus provide new fundamental know-
ledge on the catalytic domain that underpins PrPSc infectiv-
ity, which could conceivably apply to larger and more
common fibrillar structures.
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